Post Hoc Analysis of the PATRICIA Randomized Trial of the Efficacy of Human Papillomavirus Type 16 (HPV-16)/HPV-18 AS04-Adjuvanted Vaccine against Incident and Persistent Infection with Nonvaccine Oncogenic HPV Types Using an Alternative Multiplex Type-Specific PCR Assay for HPV DNA
Frank Struyf;Brigitte Colau;Cosette M. Wheeler;Paulo Naud;Suzanne Garland;Wim Quint;Song-Nan Chow;Jorge Salmerón;Matti Lehtinen;M. Rowena Del Rosario-Raymundo;Jorma Paavonen;Júlio C. Teixeira;Maria Julieta Germar;Klaus Peters;S. Rachel Skinner;Genara Limson;Xavier Castellsagué;Willy A. J. Poppe;Brian Ramjattan;Terry D. Klein;Tino F. Schwarz;Archana Chatterjee;Wiebren A. A. Tjalma;Francisco Diaz-Mitoma;David J. M. Lewis;Diane M. Harper;Anco Molijn;Leen-Jan van Doorn;Marie-Pierre David;Gary Dubin
Abstract
The efficacy of the human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against cervical infections with HPV in the Papilloma Trial against Cancer in Young Adults (PATRICIA) was evaluated using a combination of the broad-spectrum L1-based SPF10 PCR-DNA enzyme immunoassay (DEIA)/line probe assay (LiPA25) system with type-specific PCRs for HPV-16 and -18. Broad-spectrum PCR assays may underestimate the presence of HPV genotypes present at relatively low concentrations in multiple